

## **Daiichi Sankyo and Ranbaxy to Expand Hybrid Business Model in Mexico**

Tokyo Japan and Gurgaon India (August 2, 2011)

--Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) and Ranbaxy Laboratories Limited (hereafter, Ranbaxy) today announced the expansion of business in Mexico to maximize their Hybrid Business Model, encompassing both innovative and affordable, high quality, generic medicines.

Daiichi Sankyo and Ranbaxy (collectively “the Group”) have agreed to expand the Group’s business in Mexico with the launch of Olmesartan medoxomil. The product is expected to be introduced to the market before the end of 2011.

Daiichi Sankyo Mexico S.A. de C.V (DSMX), a newly established subsidiary of Daiichi Sankyo, and Ranbaxy Mexico S.A de C.V. (RMEX) will leverage the Group’s Hybrid Business Model in Mexico by utilizing the business know-how and cost advantage of Ranbaxy, thereby offering both innovative and affordable, high quality generic medicines.

“We are pleased to announce the synergistic business development with Ranbaxy in Mexico,” said Joji Nakayama, President & CEO of Daiichi Sankyo. “We are determined to work with Ranbaxy to further serve diversifying medical needs in this strongly emerging market.”

Commenting on the development, Arun Sawhney, Managing Director of Ranbaxy, said, “Mexico is an important emerging market for us, and Ranbaxy and Daiichi Sankyo will work together in providing innovative options and solutions to customers through the Hybrid Business Model.”

Daiichi Sankyo and Ranbaxy will continue to reinforce their respective and consolidated business platforms over the longer term by further accelerating their global business coordination.

*Source: Daiichi Sankyo Press Release.*